GSA Capital Partners LLP bought a new stake in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) during the second quarter, Holdings Channel reports. The institutional investor bought 19,900 shares of the biopharmaceutical company’s stock, valued at approximately $141,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Jennison Associates LLC increased its position in shares of Marinus Pharmaceuticals by 0.8% during the second quarter. Jennison Associates LLC now owns 2,757,356 shares of the biopharmaceutical company’s stock worth $19,495,000 after acquiring an additional 21,733 shares during the period. Bank of New York Mellon Corp increased its position in shares of Marinus Pharmaceuticals by 190.4% during the second quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock worth $754,000 after acquiring an additional 69,863 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Marinus Pharmaceuticals during the first quarter worth $373,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter worth $480,000. Finally, Barclays PLC purchased a new stake in shares of Marinus Pharmaceuticals during the first quarter worth $232,000. 63.64% of the stock is currently owned by institutional investors.

Shares of MRNS stock opened at $9.40 on Thursday. The firm has a market cap of $364.32 million, a P/E ratio of -11.71 and a beta of 2.59. Marinus Pharmaceuticals Inc has a 12 month low of $3.31 and a 12 month high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). analysts expect that Marinus Pharmaceuticals Inc will post -0.73 EPS for the current year.

A number of analysts have recently weighed in on the company. Mizuho reaffirmed a “buy” rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday. Cantor Fitzgerald set a $19.00 price objective on Marinus Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. BidaskClub raised Marinus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 20th. Finally, LADENBURG THALM/SH SH assumed coverage on Marinus Pharmaceuticals in a research report on Wednesday, June 6th. They set a “buy” rating and a $20.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $19.67.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Featured Article: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals Inc (NASDAQ:MRNS).

Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.